ReviewCells2021
Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Machine Learning Predicts Treatment Response and Prognostic Pathways From Whole-Blood Transcriptome in Primary Biliary Cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Epigenetic regulation and posttranslational modifications of FXR: underlying mechanisms and implications in digestive diseases.Acta pharmacologica Sinica · 2026Review
- Chlorogenic acid modulates gut microbiota and metabolites to alleviate intrahepatic cholestasis of pregnancy: Insights from 16S rRNA sequencing and metabolomics.Biochemistry and biophysics reports · 2026Article
- Mechanistic insights into atorvastatin-induced hepatotoxicity: molecular pathways, clinical relevance, and strategies for safer personalized therapy.Clinical and experimental medicine · 2026Review
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- Time-dependent modulation of FXR and Nrf2 signaling in rat models of BDL-induced cholestasis.Iranian journal of basic medical sciences · 2026Article
- Huanggan decoction ameliorates cholestatic hepatic fibrosis in rats via TGF-β1/Smad3 signaling pathway.PloS one · 2026Article
- Distinct composition and metabolic potential of biliary microbiota in patients with malignant bile duct obstruction.European journal of gastroenterology & hepatology · 2025Article
- Biliary Microbial Community and Metabolic Potential in Patients with Multiple Common Bile Duct Stones.Clinical and experimental gastroenterology · 2025Article
- Article
- Emodin and physcion alleviate cholestatic liver injury by targeting FXR: hepatoprotective components identified in processedFrontiers in pharmacology · 2025Article
- Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.Biomedicines · 2024Review
- Papaverine attenuates the progression of alpha naphthylisothiocyanate induce cholestasis in rats.Current research in pharmacology and drug discovery · 2024Article
- Human Hepatocellular response in Cholestatic Liver Diseases.Organogenesis · 2023Article
- The contributions of bacteria metabolites to the development of hepatic encephalopathy.Liver research (Beijing, China) · 2023Article
- Characteristics and metabolic potential of biliary microbiota in patients with giant common bile duct stones.Frontiers in cellular and infection microbiology · 2023Article
- Review
- Current and investigational drugs in early clinical development for portal hypertension.Frontiers in medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Recent studies on liver disease burden worldwide estimated that cirrhosis is the 11th most common cause of death globally, and there is a great need for new therapies to limit the progression of liver injuries in the early stages. Cholestasis is caused by accumulation of hydrophobic bile acids (BA) in the liver due to dysfunctional BA efflux or bile flow into the gall bladder. Therefore, strategies to increase detoxification of hydrophobic BA and downregulate genes involved in BA production are largely investigated. Farnesoid X receptor (FXR) has a central role in BA homeostasis and recent publications revealed that changes in autophagy due to BA-induced reactive oxygen species and increased anti-oxidant response via nuclear factor E2-related factor 2 (NRF2), result in dysregulation of FXR signaling. Several mechanistic studies have identified new dysfunctions of the cholestatic liver at cellular and molecular level, opening new venues for developing more performant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.